These are scary times for the global economy. And as a FTSE 100 share investor I must think extra carefully about where to invest my hard-earned cash.
The good news is there are many Footsie shares out there I’d expect to perform robustly, even as economic conditions worsen. Here are two I’d add to my portfolio today.
Associated British Foods
Associated British Foods (LSE: ABF) has two qualities that could help it outperform broader markets in the near term.
Food is something we can’t do without. Our spending on edible goods remains broadly stable during good times and bad. So ABF can expect sales of its brands like Kingsmill bread and Ovaltine drinks — as well as sugars and other ingredients — to remain robust.
Finally, I expect clothes at ABF’s Primark division to sell strongly even as broader consumer spending sinks. Clothing is another staple of everyday life and the company’s budget fashion and lifestyle offer is likely to benefit from people switching down from more expensive retailers and brands to save money.
All this explains why City analysts think the company’s earnings will rise 57% in this financial year (to September) and a further 6% next year. I’d buy the Footsie stock even though costs are rising across the group.
Oh, one final thing. ABFs dirt-cheap share price is another reason I like this FTSE 100 share a lot. At current prices of £16.15 per share, it trades on a forward price-to-earnings growth (PEG) ratio of just 0.2. A reading below 1 suggests a stock is undervalued.
GSK
GSK (LSE: GSK) — or the stock formerly known as GlaxoSmithKline — is another safe-haven FTSE 100 share I’m considering buying.
Just like food, our need for medical products doesn’t change when times get tough. This is why analysts think earnings here will rise 7% in 2022 and 2023. GSK sells some of the biggest prescription drugs out there like HIV treatment Triumeq and asthma battler Seretide/Advair.
Buying pharmaceutical shares like this comes with some risk. Failures at the lab bench can be common and regulators are happy to reject drugs that aren’t up to standard. This can result in huge additional costs for the manufacturer and a mountain of lost revenues if a product launch is delayed (or binned entirely).
Still, GSK has an excellent track record on this front that fills me, as an investor, with confidence. You don’t become one of the planet’s top 10 biggest drugs developers by sales without a reliable history of getting your drugs to market.
I’d buy GSK shares as a way to build wealth during these uncertain economic times. And I’d aim to hold them for years to cash in on rising healthcare spending in emerging markets.
